Floatz logo

Epirubicin

Non-Cutaneous Melanoma

National Cancer Institute (NCI)Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Non-Cutaneous Melanoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 3BB
Pembrolizumab
National Cancer Institute (NCI)
Phase 3B
INTERFERON ALFA-2B
National Cancer Institute (NCI)
Phase 3B
Ipilimumab
National Cancer Institute (NCI)
Phase 3B
Tbio-4101
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC
Fludarabine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →